Literature DB >> 8824004

A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL.

T H Wagner1, D L Patrick, B S Galer, R A Berzon.   

Abstract

Quality of life is important to persons experiencing migraine. This study discusses the development of a migraine-specific quality-of-life measure (MSQOL). Participants, who included migraineurs from both tertiary care centers and the community, were screened using the International Headache Society migraine criteria prior to enrollment. Internal consistency of the MSQOL was high (alpha 0.92). Reproducibility over an average of 24 days was high (intraclass correlation 0.90). Construct validity was determined by convergent validity and known groups validity. The MSQOL was compared to two other frequently used health status questionnaires; results indicate that the MSQOL more closely resembles well-being than functional status. Results also indicate that migraineurs with more symptoms, medical appointments per year to treat migraines, and migraine episodes per year have a significantly worse quality of life. The MSQOL proved valid and reliable as a self-administered measure and will be a useful tool in clinical migraine research. The information gained from its use in the clinical environment should provide important additional information about the impact of migraine on quality of life and the potential benefits of therapeutic interventions.

Entities:  

Mesh:

Year:  1996        PMID: 8824004     DOI: 10.1046/j.1526-4610.1996.3608484.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  20 in total

Review 1.  Workplace productivity. A review of the impact of migraine and its treatment.

Authors:  P Stang; R Cady; A Batenhorst; L Hoffman
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Online Data Collection in Women's Health Research: A Study of Perimenopausal Women with Migraines.

Authors:  Margaret F Moloney; Ora L Strickland; Alexa Dietrich; Stuart Myerburg
Journal:  NWSA J       Date:  2004-10-01

3.  Effect of Different Meditation Types on Migraine Headache Medication Use.

Authors:  Amy B Wachholtz; Christopher D Malone; Kenneth I Pargament
Journal:  Behav Med       Date:  2015-04-11       Impact factor: 3.104

4.  Development and testing of the Japanese version of the migraine-specific quality of life instrument.

Authors:  Sadayoshi Ohbu; Hisaka Igarashi; Hiroyuki Okayasu; Fumihiko Sakai; Joseph Green; Richard F Heller; Shunichi Fukuhara; Donald L Patrick
Journal:  Qual Life Res       Date:  2004-10       Impact factor: 4.147

Review 5.  Why HURT? A review of clinical instruments for headache management.

Authors:  Dawn C Buse; C Mark Sollars; Timothy J Steiner; Rigmor H Jensen; Mohammed A Al Jumah; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2012-06

6.  The feasibility of applying item response theory to measures of migraine impact: a re-analysis of three clinical studies.

Authors:  Jakob B Bjorner; Mark Kosinski; John E Ware
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

7.  Using item response theory to calibrate the Headache Impact Test (HIT) to the metric of traditional headache scales.

Authors:  Jakob B Bjorner; Mark Kosinski; John E Ware
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

8.  Calibration of an item pool for assessing the burden of headaches: an application of item response theory to the headache impact test (HIT).

Authors:  Jakob B Bjorner; Mark Kosinski; John E Ware
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

9.  The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument.

Authors:  S P McKenna; L C Doward; K M Davey
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

10.  Migraines and meditation: does spirituality matter?

Authors:  Amy B Wachholtz; Kenneth I Pargament
Journal:  J Behav Med       Date:  2008-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.